Primary Sclerosing Cholangitis Clinical Trial
Official title:
Trapianto di Fegato Per Colangiocarcinoma (CCA) Ilare in Associazione a Radio e Chemioterapia Neoadiuvante
Single-arm pilot clinical trial. Patients with non operable CC associated with PSC will be
subjected to liver transplantation after a neoadjuvant multimodal therapy protocol.
Cholangiocarcinoma (CC) accounts for 3% of all gastrointestinal cancers; it is more frequent
in patients with primary sclerosing cholangitis (PSC), who carry an 8%-12% risk of
developing this type of neoplasm. Only a minority of patients are suitable for resection
partly because of the anatomic position of the tumor (which often arises from the bile duct
bifurcation) and partly because of the frequently coexisting liver disease. In fact, CC is
currently considered a major contraindication to liver transplantation (OLT) at the majority
of centers, given a 5-year survival rate of 0%-35%.
New strategies have been developed for the treatment of this kind of cancer arising in PSC.
The Nebraska University group showed a 1 and 3 years survival of 55 and 45 % combining a
neoadjuvant intra bile duct barchytherapy and 5-FU based chemotherapy with liver
transplantation. University of Pittsburg proposed also a neoadjuvant protocol prior to liver
transplantation based on systemic chemotherapy and external radiotherapy reporting a 53% 5
years survival. More convincing results come from the Mayo Clinic. An accurate selection of
patients and a proper neoadjuvant multimodal therapy (chemotherapy, external radiotherapy
and intraluminal bile duct brachytherapy) lead to a 80% 5 years survival after liver
transplantation.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02239211 -
A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis
|
Phase 2 | |
| Withdrawn |
NCT03216876 -
A Study Of Ursolic Acid For Primary Sclerosing Cholangitis
|
Phase 1 | |
| Recruiting |
NCT02605213 -
Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients
|
Phase 4 | |
| Recruiting |
NCT01688024 -
Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis
|
Phase 2 | |
| Completed |
NCT03041662 -
Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
|
||
| Completed |
NCT05866809 -
Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis
|
Phase 2 | |
| Recruiting |
NCT05618145 -
National Database on Primary Sclerosing Cholangitis (PSC)
|
||
| Active, not recruiting |
NCT02446665 -
Disease Status in Primary Sclerosing Cholangitis by Elastography
|
N/A | |
| Completed |
NCT02247934 -
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
|
N/A | |
| Completed |
NCT01088607 -
Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis
|
Phase 1 | |
| Terminated |
NCT01142323 -
Pilot Study of Fenofibrate for PSC
|
Phase 1/Phase 2 | |
| Terminated |
NCT04060147 -
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
|
Phase 1 | |
| Recruiting |
NCT04133792 -
Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)
|
Phase 3 | |
| Active, not recruiting |
NCT04595825 -
CM-101 in PSC Patients -The SPRING Study
|
Phase 2 | |
| Recruiting |
NCT03183570 -
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
|
Early Phase 1 | |
| Completed |
NCT02943460 -
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
|
Phase 2 | |
| Completed |
NCT00951327 -
Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)
|
N/A | |
| Completed |
NCT04024813 -
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
|
Phase 2 | |
| Recruiting |
NCT05912387 -
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
|
Early Phase 1 | |
| Completed |
NCT02884557 -
NKT Role in the Regulation of the Inflammatory Bowel Disease
|
N/A |